Researchers have been able to show that a natural compound previously shown to extend lifespan in non-vertebrate organisms can also do so in at least one vertebrate species.
The findings, reported by Alessandro Cellerino of the Scuola Normale Superiore, Pisa, and colleagues, support the potential utility of the compound in human aging research.

The development of drugs able to retard the onset of aging-related diseases and improve quality of life in the elderly is a growing focus of aging research and public health in modern society. But the successful development of drugs aimed at aging-related diseases needs to face the challenge posed by the lifespan of the available animal models--mammalian models for aging are relatively long-lived and aren't as easily studied as shorter-lived species.

Resveratrol is an organic compound naturally present in grapes -- and particularly enriched in red wine -- and was previously shown to prolong lifespan in non-vertebrate model organisms such as yeast, the worm C. elegans, and the fruit fly Drosophila.
However, until now, life-long pharmacological trials were performed in the worm or fly model organisms because of their very small size, very short natural lifespan, and affordable cultivation costs. Laboratory mice, on the other hand, live more than two years and are relatively expensive to maintain, making large-scale, life-long pharmacological trials in mice unaffordable.

Recently, a small fish species with a captive lifespan of only three months was described by Cellerino and colleagues. In the new work, the researchers used this short-lived fish to test the effects of Resveratrol on aging-related physiological decay.
The researchers added Resveratrol to daily fish food and found that this treatment increased longevity and also retarded the onset of aging-related decays in memory and muscular performance.

Resveratrol appears to be the first molecule to consistently cause life extension across very different animal groups such as worms, insects, and fish, and it could become the starting molecule for the design drugs for the prevention of human aging-related diseases.

Source: Cell, 2006


XagenaMedicine2006